UBS upgraded Alkermes (NASDAQ:ALKS) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor ...

Analysts have recently evaluated Alkermes and provided 12-month price targets. The average target is $42.17, accompanied by a ...

DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45 th ...

Inc. The Alkermes Pathways Research Awards logo is a service mark of Alkermes, Inc. Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and ...

Alkermes has shown more of the data that ... pushing into phase 3 after avoiding the safety problems that rocked Jazz Pharmaceuticals’ rival candidate. Jazz pumped the brakes because of reports ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Eledon Pharmaceuticals (ELDN – Research Report) and Legend ...

Alkermes PLC (NASDAQ:ALKS) is a fast-growing pharmaceutical company headquartered in Dublin, Ireland. Not only does the company have an extensive pipeline of product candidates being developed ...

We understand the significant potential impacts that pharmaceuticals can have on ... Preserving the Biodiversity of our Local Communities Alkermes is committed to conserving and enhancing ...

Shareholders in Alkermes have quelled a challenge from Sarissa Capital, reelecting seven board members and rejecting three nominees from the activist investor, the Ireland-based drugmaker said.

DUBLIN, April 26, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2023. "During the first quarter we made continued progress across our ...

As we can see, Alkermes is performing better than its sector in the calendar year. Another stock in the Medical sector, Actinium Pharmaceuticals (ATNM), has outperformed the sector so far this year.